<DOC>
	<DOCNO>NCT01745887</DOCNO>
	<brief_summary>This Phase 1b , multi-center , double-masked , randomize , placebo-controlled , parallel-group study design evaluate safety biological activity two dose EBI-005 ophthalmic solution versus placebo subject moderate severe Dry Eye Syndrome . Approximately 72 subject enrol randomize study 9 center locate United States ( US ) . Subjects enrol two group cohort . The first enrollment group consist 33 subject .</brief_summary>
	<brief_title>A Multi-Center Study Subjects With Dry Eye Syndrome</brief_title>
	<detailed_description>- To investigate safety tolerability EBI-005 ophthalmic solution compare placebo treatment patient moderate severe Dry Eye Syndrome ( DES ) . - To evaluate pharmacokinetic ( PK ) parameter immunogenicity two different dos EBI-005 ophthalmic solution . - To investigate biological activity multiple dose EBI-005 ophthalmic solution compare placebo assess objective subjective assessment . - To investigate comparative dose response two different dos EBI-005 ophthalmic solution . - To investigate comparative tolerability two different dos EBI-005 ophthalmic solution . - To identify key biomarkers diagnosis management subject DES .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<criteria>Provide write informed consent prior study related procedure Are 18 year age old Are woman child bear potential ( WOCBP ) nonpregnant , nonlactating sexually inactive ( abstinent ) 14 day prior Visit 1 Are willing able follow instruction present require study visit duration study Have history Dry Eye Syndrome eye support previous clinical diagnosis Have ongoing Dry Eye Syndrome , eye eye , define follow criterion : 1 . A score ≥23 OSDI 2 . A corneal fluorescein stain score ≥6 ( NEI scale ) Have normal lid anatomy Are willing withhold artificial tear duration study , exception study provide artificial tear : Refresh Plus® . Subjects may : Have previously use IL1 blocker ( e.g. , Anakinra , Rilonacept Ilaris ) . Have OSDI score ≥90 Have corneal fluorescein stain score 15 ( NEI scale ) . NOTE : If one two eye corneal fluorescein stain score 15 , subject may eligible . Within 30 day prior screen visit ( Visit 1 ) take : Topical cyclosporine ( Restasis® ) Ocular corticosteroid Autologous serum Topical ocular antibiotic Topical ocular antihistamine mast cell stabilizer Topical nasal vasoconstrictor Within 30 day prior screen visit ( Visit 1 ) alter dose tetracycline compound ( tetracycline , doxycycline minocycline ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Dry Eye Syndrome</keyword>
	<keyword>Interleukin 1 Receptor Inhibitor</keyword>
</DOC>